Skip to main content
    B

    Bio-Techne Corp (TECH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $72.79
    -0.01 (-0.01%)

    Market Cap: $11.44B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Bio-Techne Corp (TECH) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Bio-Techne reported revenue of $1.22B for the fiscal year ended Jun 30, 2026, down 0.4% from the year before. That year, net income was $181.86M with a net margin of 15.0%, operating cash flow was $292.07M and free cash flow was $263.22M. The quarter ended Sep 30, 2026 had revenue of $299.71M and net income of $28.29M.

    Revenue and Margins

    The operating margin was 20.7% in the fiscal year ended Jun 2026. Over the 9 years to Jun 2026, revenue grew from $563.00M, a compound annual rate of 9.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Jun 2026$1.22B-0.4%65.8%20.7%15.0%
    Jun 2025$1.22B+5.2%64.8%8.4%6.0%
    Jun 2024$1.16B+2.0%66.4%17.8%14.5%
    Jun 2023$1.14B+2.8%67.7%26.3%25.1%
    Jun 2022$1.11B+18.7%68.4%26.8%23.8%
    Jun 2021$931.03M+26.0%68.0%25.5%15.0%
    Jun 2020$738.69M+3.5%65.4%21.3%31.0%
    Jun 2019$714.01M+11.0%66.3%20.5%13.5%
    Jun 2018$642.99M+14.2%67.2%21.2%19.6%
    Jun 2017$563.00MN/A66.5%21.4%13.5%
    Annual, fiscal years ended Jun 2017 to Jun 2026

    Income Statement

    In the fiscal year ended Jun 2026, net income rose 147.8% from the year before. In the quarter ended Sep 2026, net income fell 25.9% from the same quarter a year earlier.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Revenue$1.22B$1.22B$1.16B$1.14B$1.11B$931.03M$738.69M$714.01M$642.99M$563.00M
    Cost of revenue$415.97M$429.36M$389.33M$366.89M$349.10M$298.18M$255.50M$240.51M$210.85M$188.46M
    Gross profit$799.07M$790.27M$769.73M$769.82M$756.50M$632.85M$483.19M$473.49M$432.14M$374.54M
    Research and development$94.77M$99.50M$96.66M$92.49M$87.14M$70.60M$65.19M$62.41M$55.33M$53.51M
    Operating income$251.89M$102.25M$206.69M$298.94M$296.59M$237.30M$157.42M$146.72M$136.18M$120.58M
    Net income$181.86M$73.40M$168.10M$285.44M$263.10M$139.59M$229.30M$96.07M$126.15M$76.09M
    EBITDA$343.45M$212.99M$309.81M$453.70M$412.97M$249.40M$377.81M$211.32M$200.19M$179.05M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$299.71M$321.19M$311.42M$295.88M$286.56M$316.96M$316.18M$297.03M$289.46M$306.10M$303.43M$272.60M
    Gross profit$196.62M$211.39M$208.29M$191.28M$188.11M$198.81M$214.56M$193.89M$183.02M$203.35M$204.60M$176.59M
    Operating income$36.60M$74.28M$75.50M$54.46M$47.66M-$23.86M$38.71M$47.42M$39.99M$45.82M$67.00M$38.00M
    Net income$28.29M$54.62M$51.05M$38.01M$38.19M-$17.68M$22.59M$34.89M$33.60M$40.59M$49.06M$27.46M
    Last 12 quarters

    Balance Sheet

    As of Jun 2026, cash and equivalents exceeded total debt of $200.00M by $64.71M.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Total assets$2.59B$2.56B$2.70B$2.64B$2.29B$2.26B$2.03B$1.88B$1.59B$1.56B
    Current assets$744.40M$608.30M$617.42M$621.48M$605.56M$510.61M$520.92M$412.61M$398.37M$348.02M
    Cash and equivalents$264.71M$162.19M$151.79M$180.57M$172.57M$199.09M$146.63M$100.89M$121.99M$91.61M
    Total liabilities$478.50M$639.06M$635.02M$672.18M$588.79M$691.72M$646.40M$718.82M$514.14M$608.59M
    Short-term debt$0$14.10M$12.92M$3.50M$12.50M$16.50M$18.44M$15.90M$0$65.10M
    Long-term debt$200.00M$346.00M$319.00M$350.00M$243.41M$328.83M$344.24M$492.66M$339.00M$343.77M
    Shareholder equity$2.11B$1.92B$2.07B$1.97B$1.70B$1.56B$1.38B$1.17B$1.08B$949.63M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$2.64B$2.59B$2.55B$2.52B$2.53B$2.56B$2.64B$2.67B$2.74B$2.70B$2.72B$2.73B
    Total liabilities$471.13M$478.50M$465.30M$511.71M$560.33M$639.06M$626.23M$591.93M$597.37M$635.02M$706.79M$767.19M
    Cash and equivalents$350.04M$264.71M$209.82M$172.88M$144.96M$162.19M$140.67M$177.55M$187.54M$151.79M$139.91M$130.13M
    Shareholder equity$2.17B$2.11B$2.09B$2.01B$1.97B$1.92B$2.02B$2.08B$2.14B$2.07B$2.01B$1.96B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Jun 2026, free cash flow was 90.1% of operating cash flow. Dividends and share repurchases together came to 34.8% of it.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Operating cash flow$292.07M$287.56M$298.98M$254.39M$325.27M$352.16M$205.22M$181.62M$170.37M$143.72M
    Capital expenditures$28.85M$31.01M$62.88M$38.24M$44.91M$44.30M$51.74M$25.41M$20.93M$15.18M
    Free cash flow$263.22M$256.55M$236.10M$216.15M$280.36M$307.86M$153.47M$156.21M$149.43M$128.54M
    Dividends paid$49.92M$50.39M$50.42M$50.28M$50.19M$49.62M$48.90M$48.36M$47.97M$47.33M
    Share repurchases$41.67M$275.73M$80.04M$19.56M$160.95M$43.18M$50.11M$15.40M$0$0
    Investing cash flow-$18.19M-$35.18M-$203.03M-$265.65M-$96.85M-$243.52M$27.09M-$336.80M-$38.71M-$305.95M
    Financing cash flow-$169.11M-$253.91M-$122.40M$22.62M-$242.85M-$62.55M-$183.80M$134.38M-$99.19M$189.11M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$73.11M$95.42M$86.66M$82.41M$27.59M$98.20M$41.12M$84.35M$63.89M$75.50M$80.99M$83.12M
    Capital expenditures$5.92M$8.48M$9.09M$5.92M$5.36M$4.89M$10.12M$6.82M$9.17M$17.98M$16.44M$14.86M
    Free cash flow$67.20M$86.94M$77.58M$76.49M$22.22M$93.31M$31.00M$77.53M$54.72M$57.52M$64.55M$68.25M
    Last 12 quarters

    Frequently Asked Questions About TECH

    What is Bio-Techne's annual revenue?

    Bio-Techne reported revenue of $1.22B for the fiscal year ended Jun 30, 2026.

    How fast is Bio-Techne's revenue growing?

    Revenue was down 0.4% for the fiscal year ended Jun 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 2.2%.

    Is Bio-Techne profitable?

    Yes. Bio-Techne reported net income of $181.86M for the fiscal year ended Jun 30, 2026, with a net margin of 15.0%.

    How much free cash flow does TECH generate?

    For the fiscal year ended Jun 30, 2026, operating cash flow of $292.07M minus capital expenditures of $28.85M produced free cash flow of $263.22M.

    How much debt does Bio-Techne have?

    The balance sheet dated Jun 30, 2026 reported long-term debt of $200.00M, short-term debt of $0 and cash and equivalents of $264.71M.